Scutellarin Ameliorates Learning and Memory Deficit via Suppressing β-Amyloid Formation and Microglial Activation in Rats with Chronic Cerebral Hypoperfusion

The American Journal of Chinese Medicine
Jung-Won ShinNak-Won Sohn

Abstract

Chronic cerebral hypoperfusion is considered as a pivotal factor of cognitive impairment that occurs in cerebrovascular diseases. This study investigated the ameliorating effect of scutellarin (SCT) on spatial cognitive impairment and β-amyloid (Aβ) formation in rats with chronic cerebral hypoperfusion induced by permanent bilateral common carotid artery occlusion (pBCAO). SCT is a flavonoid in medicinal herb of Erigeron breviscapus (vant.) Hand. Mazz. known to have neuroprotective, antioxidative and anti-inflammatory effects. However, the beneficial effect and pivotal mechanism of SCT on cognitive impairment are still unclear. SCT was treated orally with two doses (10 or 30 mg/kg) for 4 weeks. Results of Morris water maze test performed on the ninth week after pBCAO revealed that SCT (30 mg/kg)-treated rats had significantly shortened escape latencies in acquisition training trials, significantly prolonged swimming time at the platform and its surrounding zone, significant increase in memory score, significant reduction in the number of target heading, and significant reduction in the time required for the first target heading during the retention trial compared to rats in the sham-control group. SCT significantly inhibited th...Continue Reading

References

Sep 24, 1993·Annals of the New York Academy of Sciences·R N KalariaG Perry
Apr 30, 1999·Progress in Neurobiology·W J StreitN A Pennell
Aug 31, 2001·Microscopy Research and Technique·H Aldskogius
Apr 12, 2003·Clinical and Experimental Pharmacology & Physiology·Tatsuo OtoriAkiro Terashi
May 5, 2004·Planta medica·Hao Hong, Guo-Qing Liu
Jan 22, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hong LiuHuibi Xu
Jul 4, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Xiulian SunWeihong Song
Sep 1, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·John T O'Brien
Nov 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Xiulian SunWeihong Song
Nov 18, 2009·Nature Reviews. Neurology·Majid FotuhiPeter J Whitehouse
Jan 12, 2010·Journal of Alzheimer's Disease : JAD·Edith G McGeer, Patrick L McGeer
Apr 14, 2010·Ageing Research Reviews·Jack C de la Torre
Oct 6, 2011·Journal of Alzheimer's Disease : JAD·Benjamin P AustinVivek Prabhakaran
Nov 3, 2011·Journal of Alzheimer's Disease : JAD·Seyyed Hani Moussavi NikMichael Lardelli
Jun 29, 2012·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Li-Li GuoJin-Shan Shi
Sep 8, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Lihua QianNian-Guang Li
Aug 9, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Zhiyuan ZhuXu Shen
Oct 8, 2014·Physiological Reviews·Milos Pekny, Marcela Pekna
Aug 20, 2016·Science·Richard M Ransohoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Microglia

Microglia are a type of glial cell found throughout the brain and spinal cord. Microglia have been found to be associated with Alzheimer's disease development and progression. Here are the latest discoveries pertaining to Alzheimer's disease and microglia.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.